Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $CAI vs $TGTX | Chartloom

Compare

$CAI vs $TGTX

Caris Life Sciences Inc · TG Therapeutics Inc

CAI

Caris Life Sciences Inc

TGTX

TG Therapeutics Inc

Compare $CAI vs $TGTX

Comparing Caris Life Sciences Inc and TG Therapeutics Inc

CAICaris Life Sciences Inc

TGTXTG Therapeutics Inc

CAICaris Life Sciences Inc

Market cap

$8.35B

P/E (TTM)

79.46x

Forward P/E (NTM)

101.06x

Forward P/S (NTM)

7.44x

Rev growth (TTM)

24.4%

YTD performance

9.5%

52W performance

-3.1%

FCF yield

1.5%

TGTXTG Therapeutics Inc

Market cap

$8.32B

P/E (TTM)

19.36x

Forward P/E (NTM)

27.77x

Forward P/S (NTM)

7.37x

Rev growth (TTM)

76.1%

YTD performance

85.6%

52W performance

61.0%

FCF yield

0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CAI

TGTX

Detailed metrics comparison

CAI

Caris Life Sciences Inc

TGTX

TG Therapeutics Inc

Market Cap

CAI$8.35B

TGTX$8.32B

Enterprise Value

CAI$8.05B

TGTX$8.58B

Price

CAI$29.53

TGTX$54.34

P/E Ratio

CAI79.46x

TGTX19.36x

P/S Ratio

CAI8.44x

TGTX10.40x

EV/Sales

CAI8.13x

TGTX10.73x

EV/EBITDA

CAI45.67x

TGTX61.91x

P/B Ratio

CAI14.18x

TGTX14.03x

P/FCF Ratio

CAI67.34x

TGTX478.48x

EV/FCF

CAI64.94x

TGTX493.60x

PEG Ratio

CAIN/A

TGTX0.83x

Forward P/E (NTM)

CAI101.06x

TGTX27.77x

Forward P/S (NTM)

CAI7.44x

TGTX7.37x

Revenue (TTM)

CAI$990M

TGTX$800M

Revenue Growth (YoY)

CAI24.4%

TGTX76.1%

Forward Rev Growth

CAI18.2%

TGTX35.6%

Gross Margin (TTM)

CAI69.7%

TGTX82.4%

Operating Margin (TTM)

CAI12.7%

TGTX15.9%

EBITDA Margin (TTM)

CAI17.6%

TGTX17.1%

Net Margin (TTM)

CAI10.6%

TGTX55.2%

FCF Margin (TTM)

CAI12.5%

TGTX2.2%

Net Income (TTM)

CAI$105M

TGTX$441M

FCF (TTM)

CAI$124M

TGTX$17M

EPS (TTM)

CAI$0.37

TGTX$2.81

ROE (TTM)

CAI18.8%

TGTX72.3%

ROA (TTM)

CAI9.3%

TGTX33.6%

ROIC (TTM)

CAI11.2%

TGTX39.9%

Cash

CAI$691M

TGTX$483M

Debt

CAI$393M

TGTX$745M

Net Cash/Debt

CAI$298M

TGTX$-263M

Current Ratio (TTM)

CAI5.53x

TGTX4.27x

Quick Ratio (TTM)

CAI4.78x

TGTX3.72x

Debt/Equity (TTM)

CAI0.66x

TGTX1.23x

Debt/Assets (TTM)

CAI0.0%

TGTX0.0%

Interest Coverage (TTM)

CAIN/A

TGTXN/A

Net Debt/EBITDA (TTM)

CAI0.00x

TGTX0.00x

Beta

CAI0.40

TGTX1.82

52W Performance

CAI-3.1%

TGTX61.0%

YTD Performance

CAI9.5%

TGTX85.6%

% from 52W High

CAI-12.2%

TGTX-8.4%

% from 52W Low

CAI108.1%

TGTX103.1%

Asset Turnover (TTM)

CAI0.88x

TGTX0.61x

FCF Yield (TTM)

CAI1.5%

TGTX0.2%

Earnings Yield (TTM)

CAI1.3%

TGTX5.3%

Dividend Yield (TTM)

CAIN/A

TGTXN/A

Rule of 40

CAI37.0

TGTX78.3

EV/GP/RG

CAI0.86

TGTX0.31

Ticker research

View CAI research View TGTX research

Metric	CAI Caris Life Sciences Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.35B	$8.32B
Enterprise Value	$8.05B	$8.58B
Price	$29.53	$54.34
P/E Ratio	79.46x	19.36x
P/S Ratio	8.44x	10.40x
EV/Sales	8.13x	10.73x
EV/EBITDA	45.67x	61.91x
P/B Ratio	14.18x	14.03x
P/FCF Ratio	67.34x	478.48x
EV/FCF	64.94x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	101.06x	27.77x
Forward P/S (NTM)	7.44x	7.37x
Revenue & Growth
Revenue (TTM)	$990M	$800M
Revenue Growth (YoY)	24.4%	76.1%
Forward Rev Growth	18.2%	35.6%
Profitability
Gross Margin (TTM)	69.7%	82.4%
Operating Margin (TTM)	12.7%	15.9%
EBITDA Margin (TTM)	17.6%	17.1%
Net Margin (TTM)	10.6%	55.2%
FCF Margin (TTM)	12.5%	2.2%
Net Income (TTM)	$105M	$441M
FCF (TTM)	$124M	$17M
EPS (TTM)	$0.37	$2.81
ROE (TTM)	18.8%	72.3%
ROA (TTM)	9.3%	33.6%
ROIC (TTM)	11.2%	39.9%
Financial Health
Cash	$691M	$483M
Debt	$393M	$745M
Net Cash/Debt	$298M	$-263M
Current Ratio (TTM)	5.53x	4.27x
Quick Ratio (TTM)	4.78x	3.72x
Debt/Equity (TTM)	0.66x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.82
52W Performance	-3.1%	61.0%
YTD Performance	9.5%	85.6%
% from 52W High	-12.2%	-8.4%
% from 52W Low	108.1%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.61x
FCF Yield (TTM)	1.5%	0.2%
Earnings Yield (TTM)	1.3%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	78.3
EV/GP/RG	0.86	0.31
Ticker research	View CAI research	View TGTX research

Valuation

P/E Ratio

TGTX

19.36x

CAI

79.46x

P/S Ratio

CAI

8.44x

TGTX

10.40x

EV/FCF

CAI

64.94x

TGTX

493.60x

Growth & revenue

Revenue Growth TTM

TGTX

76.1%

CAI

24.4%

Forward Revenue Growth

TGTX

35.6%

CAI

18.2%

Profitability & performance

Gross Margin

TGTX

82.4%

CAI

69.7%

ROE

TGTX

72.3%

CAI

18.8%

FCF Yield %

CAI

1.5%

TGTX

0.2%

52-Week Performance

TGTX

61.0%

CAI

-3.1%

Detailed metrics comparison

CAI

Caris Life Sciences Inc

TGTX

TG Therapeutics Inc

Market Cap

CAI$8.35B

TGTX$8.32B

Enterprise Value

CAI$8.05B

TGTX$8.58B

Price

CAI$29.53

TGTX$54.34

P/E Ratio

CAI79.46x

TGTX19.36x

P/S Ratio

CAI8.44x

TGTX10.40x

EV/Sales

CAI8.13x

TGTX10.73x

EV/EBITDA

CAI45.67x

TGTX61.91x

P/B Ratio

CAI14.18x

TGTX14.03x

P/FCF Ratio

CAI67.34x

TGTX478.48x

EV/FCF

CAI64.94x

TGTX493.60x

PEG Ratio

CAIN/A

TGTX0.83x

Forward P/E (NTM)

CAI101.06x

TGTX27.77x

Forward P/S (NTM)

CAI7.44x

TGTX7.37x

Revenue (TTM)

CAI$990M

TGTX$800M

Revenue Growth (YoY)

CAI24.4%

TGTX76.1%

Forward Rev Growth

CAI18.2%

TGTX35.6%

Gross Margin (TTM)

CAI69.7%

TGTX82.4%

Operating Margin (TTM)

CAI12.7%

TGTX15.9%

EBITDA Margin (TTM)

CAI17.6%

TGTX17.1%

Net Margin (TTM)

CAI10.6%

TGTX55.2%

FCF Margin (TTM)

CAI12.5%

TGTX2.2%

Net Income (TTM)

CAI$105M

TGTX$441M

FCF (TTM)

CAI$124M

TGTX$17M

EPS (TTM)

CAI$0.37

TGTX$2.81

ROE (TTM)

CAI18.8%

TGTX72.3%

ROA (TTM)

CAI9.3%

TGTX33.6%

ROIC (TTM)

CAI11.2%

TGTX39.9%

Cash

CAI$691M

TGTX$483M

Debt

CAI$393M

TGTX$745M

Net Cash/Debt

CAI$298M

TGTX$-263M

Current Ratio (TTM)

CAI5.53x

TGTX4.27x

Quick Ratio (TTM)

CAI4.78x

TGTX3.72x

Debt/Equity (TTM)

CAI0.66x

TGTX1.23x

Debt/Assets (TTM)

CAI0.0%

TGTX0.0%

Interest Coverage (TTM)

CAIN/A

TGTXN/A

Net Debt/EBITDA (TTM)

CAI0.00x

TGTX0.00x

Beta

CAI0.40

TGTX1.82

52W Performance

CAI-3.1%

TGTX61.0%

YTD Performance

CAI9.5%

TGTX85.6%

% from 52W High

CAI-12.2%

TGTX-8.4%

% from 52W Low

CAI108.1%

TGTX103.1%

Asset Turnover (TTM)

CAI0.88x

TGTX0.61x

FCF Yield (TTM)

CAI1.5%

TGTX0.2%

Earnings Yield (TTM)

CAI1.3%

TGTX5.3%

Dividend Yield (TTM)

CAIN/A

TGTXN/A

Rule of 40

CAI37.0

TGTX78.3

EV/GP/RG

CAI0.86

TGTX0.31

Ticker research

View CAI research View TGTX research

Metric	CAI Caris Life Sciences Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.35B	$8.32B
Enterprise Value	$8.05B	$8.58B
Price	$29.53	$54.34
P/E Ratio	79.46x	19.36x
P/S Ratio	8.44x	10.40x
EV/Sales	8.13x	10.73x
EV/EBITDA	45.67x	61.91x
P/B Ratio	14.18x	14.03x
P/FCF Ratio	67.34x	478.48x
EV/FCF	64.94x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	101.06x	27.77x
Forward P/S (NTM)	7.44x	7.37x
Revenue & Growth
Revenue (TTM)	$990M	$800M
Revenue Growth (YoY)	24.4%	76.1%
Forward Rev Growth	18.2%	35.6%
Profitability
Gross Margin (TTM)	69.7%	82.4%
Operating Margin (TTM)	12.7%	15.9%
EBITDA Margin (TTM)	17.6%	17.1%
Net Margin (TTM)	10.6%	55.2%
FCF Margin (TTM)	12.5%	2.2%
Net Income (TTM)	$105M	$441M
FCF (TTM)	$124M	$17M
EPS (TTM)	$0.37	$2.81
ROE (TTM)	18.8%	72.3%
ROA (TTM)	9.3%	33.6%
ROIC (TTM)	11.2%	39.9%
Financial Health
Cash	$691M	$483M
Debt	$393M	$745M
Net Cash/Debt	$298M	$-263M
Current Ratio (TTM)	5.53x	4.27x
Quick Ratio (TTM)	4.78x	3.72x
Debt/Equity (TTM)	0.66x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.82
52W Performance	-3.1%	61.0%
YTD Performance	9.5%	85.6%
% from 52W High	-12.2%	-8.4%
% from 52W Low	108.1%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.61x
FCF Yield (TTM)	1.5%	0.2%
Earnings Yield (TTM)	1.3%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	78.3
EV/GP/RG	0.86	0.31
Ticker research	View CAI research	View TGTX research